Clinical Trial Detail

NCT ID NCT03785210
Title Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

hepatocellular carcinoma

pancreatic cancer

Therapies

Nivolumab + Tadalafil + Vancomycin

Age Groups: adult senior

No variant requirements are available.